翰森制药 | 昕越®第二项适应症获批上市，适用于免疫球蛋白G4相关性疾病成人患者

参考文献：

[1] Inebilizumab for Treatment of IgG4-Related Disease | New England Journal of Medicine

[2]Perugino, C. A., & Stone, J. H. (2020). IgG4-related disease: an update on pathophysiology and implications for clinical care. Nature Reviews Rheumatology, 16(12), 702-714.

[3] Stone, J. H., Zen, Y., & Deshpande, V. (2012). IgG4-Related Disease. New England Journal of Medicine, 366(6), 539-551.

[4] Floreani, A., Okazaki, K., Uchida, K., & Gershwin, M. E. (2021). IgG4-related disease: Changing epidemiology and new thoughts on a multisystem disease. Journal of Translational Autoimmunity, 4, 100074.

[5] Wallace, Z. S., Mattoo, H., Mahajan, V. S., Kulikova, M., Lu, L., Deshpande, V., Choi, H. K., Pillai, S., & Stone, J. H. (2016). Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology, 55(6), 1000-1008.

[6] Zhang, W., & Stone, J. H. (2019). Management of IgG4-related disease. The Lancet Rheumatology, 1(1), e55-e65.

[7] Wolfson, A. R., & Hamilos, D. L. (2017). Recent advances in understanding and managing IgG4-related disease. F1000Research, 6, 185.

[8]https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.41120

[9]https://pubmed.ncbi.nlm.nih.gov/22218969/